Table 1.
Baseline actinic keratosis (AK) characteristics in treatment zones and clinically equivalent zones (CEZs)
| Characteristics | 5% 5‐Fluorouracil | 5% Imiquimod | Sunscreen | Total | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Intervention, all sites | HN | UL | CEZ | Intervention, all sites | HN | UL | CEZ | Intervention, all sites | HN | UL | CEZ | Intervention, all sites | CEZ | |
| Participants, n | 13 | 7 | 6 | 8 | 14 | 7 | 7 | 8 | 13 | 6 | 7 | 9 | 40 | 25 |
| AKs, total n | 178 | 103 | 75 | 104 | 214 | 98 | 116 | 106 | 178 | 74 | 104 | 123 | 570 | 333 |
| Median AKs, n (range) | 12 (10–25) | 12 (10–25) | 12 (10–25) | 11·5 (10–21) | 13 (10–29) | 13 (10–25) | 15 (10–29) | 12·5 (6–26) | 13 (5–21) | 11·5 (10–16) | 17 (5–21) | 14 (5–17) | 12·5 (5–29) | 13 (5–26) |
| Median AK area (range), cm2 | 0·4 (0.1–5·5) | 0·5 (0·2–5·5) | 0·4 (0·1–4) | 0·4 (0·1–5·5) | 0·4 (0·1–3) | 0·4 (0·2–3) | 0·4 (0·1–2) | 0·55 (0·1–6·5) | 0·38 (0·1–9) | 0·3 (0·2–3) | 0·4 (0·1–9) | 0·4 (0·1–5) | 0·4 (0·1–9) | 0·4 (0·1–6·5) |
| KSS; AKs, n (%) | ||||||||||||||
| 1 | 112 (63) | 59 (57) | 53 (71) | 62 (60) | 121 (57) | 59 (60) | 62 (53) | 55 (52) | 113 (63) | 48 (65) | 65 (62) | 80 (65) | 346 (61) | 197 (59) |
| 2 | 59 (33) | 38 (37) | 21 (28) | 33 (32) | 76 (36) | 30 (31) | 46 (40) | 46 (43) | 57 (32) | 26 (35) | 31 (30) | 36 (29) | 192 (34) | 115 (35) |
| 3 | 7 (4) | 6 (6) | 1 (1) | 9 (9) | 17 (8) | 9 (9) | 8 (7) | 5 (5) | 8 (4) | 0 (0) | 8 (8) | 7 (6) | 32 (6) | 21 (6) |
| Mean; median | 1·41; 1·0 | 1·49; 1·0 | 1·31; 1·0 | 1·49; 1·0 | 1·51; 1·0 | 1·49; 1·0 | 1·53; 1·0 | 1·53; 1 | 1·41; 1·0 | 1·35; 1·0 | 1·43; 1 | 1·41; 1·0 | 1·45; 1·0 | 1·47; 1·0 |
| ESS; AKs, n (%) | ||||||||||||||
| 1 | 122 (69) | 77 (75) | 45 (60) | 54 (52) | 154 (72) | 72 (73) | 82 (71) | 53 (50) | 127 (71) | 60 (81) | 67 (64) | 75 (61) | 403 (71) | 182 (55) |
| 2 | 56 (31) | 26 (25) | 30 (40) | 50 (48) | 60 (28) | 26 (27) | 34 (29) | 53 (50) | 51 (29) | 14 (19) | 37 (36) | 48 (39) | 167 (29) | 151 (45) |
| TAB, median (range)a | 6·6 (2–30) | 8·1 (2–30) | 6·1 (2·4–9) | 6·3 (2–21) | 6·6 (2·2–23·2) | 6·0 (3·3–10·4) | 7·5 (2·2–23·2) | 6·35 (4·8–31·2) | 5·6 (2·2–22·5) | 6·0 (2·2–5·6) | 6·8 (2·2–22·5) | 6·3 (2–17) | 6·15 (2–30) | 6·3 (2–31·2) |
aTotal AK burden (TAB) score for each patient was derived as a product of the total AK count, median keratosis grade and median area.
ESS, Erythema Scale Score; HN, right/left cheek and nose, right/left forehead, scalp, upper chest; KSS, Keratosis Scale Score; UL, upper limbs